Forgot Password?
Return to Course Listing

CME: The next frontier in myelofibrosis management


Activity Description / Statement of Need:

In this online, self-learning activity:

Myelofibrosis (MF) is a hematologic malignancy characterized by fibrosis buildup in the bone marrow, inadequate hematopoiesis, and splenomegaly. MF is a rare form of cancer, with an incidence of about 0.4 per 100,000 person-years in the United States. MF is the most aggressive form of the Philadelphia-negative, BCR-ABL1 chronic myeloproliferative neoplasms, with a five-year mortality rate of 51%. In patients with other comorbidities at the time of or after diagnosis, such as diabetes, hypertension, pulmonary diseases, or obesity, even greater reductions in lifespan can be expected. It has a considerable effect on patient quality of life and is associated not only with feelings of fear, anger, and grief common of an oncologic diagnosis, but also a gradual loss of ability to perform activities of daily living and hobbies. MF imposes a significant financial burden through direct and indirect costs, and patients who are diagnosed at a younger age often become unemployed as the disease progresses.

Target Audience:

The following HCPs: hematologists and oncologists in the community and academic settings; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with MF.

Commercial Support Disclosure: This program is supported by an educational grant from CTI BioPharma.

This activity is free of charge.

Release Date: March 08, 2023 -- Expiration Date: March 08, 2024

Faculty: Eric Tam, MD


Faculty introduction, disclosures

Myelofibrosis overview

  • Epidemiology
  • Disease features and presentation
  • Diagnosis
  • Burden of disease
    • Physical function effects
    • Effects on mental wellbeing
    • Survival

Treatment decision making in MF

  • Factors influencing treatment decisions
    • Risk stratification
    • Low vs higher risk
    • Symptoms
    • Transfusion candidates
    • Presence of thrombocytopenia
    • Response to therapy
  • Pharmacotherapeutic agents and targets
    • Approved JAK inhibitors
    • Emerging JAK inhibitors
    • Novel approaches
      • BCL inhibition
      • XPO1/CRM1 inhibition
      • Anti-CD123
      • BET inhibition
      • MDM2 inhibition
  • Clinical trial data
    • Safety and efficacy
    • Ongoing clinical trials: what’s next?
  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the burden of disease of MF.
  • Assign a risk stratification category to a MF patient case to determine the optimal treatment approach.
  • Recall the molecular drivers of disease in patients with MF.
  • Contrast new and emerging treatment options, including efficacy, safety, and anticipated role in MF management.
  • Develop a treatment plan for a MF patient using guideline-directed and evidence-based therapies.


ACCME Activity #202412824


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Eric Tam, MD, Assistant Professor of Clinical Medicine, Keck Medicine of USC, received financial compensation for speakers bureau from Medical Education Speakers Network.


Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from CTI BioPharma.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Strategies to prevent complications of sickle cell disease

Updates in the management of polyneuropathy of hereditary transthyretin amyloidosis (ATTR): Treating the condition head-on

Myeloma bone disease: Monitoring and management

Preventing and mitigating skeletal-related events in breast cancer